CR20220116A - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- CR20220116A CR20220116A CR20220116A CR20220116A CR20220116A CR 20220116 A CR20220116 A CR 20220116A CR 20220116 A CR20220116 A CR 20220116A CR 20220116 A CR20220116 A CR 20220116A CR 20220116 A CR20220116 A CR 20220116A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- sup
- heterocyclic compounds
- processes
- manufacturing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (I): en donde A, L, Q, U, V, W, X, Z, m, n y R<sup>1</sup> a R<sup>4</sup> son tal como se indica en la presente, en donde las composiciones incluyen los compuestos, procedimientos de fabricación de los compuestos y métodos de uso de los compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19198974 | 2019-09-23 | ||
CN2020109184 | 2020-08-14 | ||
PCT/EP2020/076228 WO2021058416A1 (en) | 2019-09-23 | 2020-09-21 | Heterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220116A true CR20220116A (es) | 2022-04-20 |
Family
ID=72659185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220116A CR20220116A (es) | 2019-09-23 | 2020-09-21 | Compuestos heterocíclicos |
Country Status (15)
Country | Link |
---|---|
US (2) | US20210107921A1 (es) |
EP (1) | EP4034239A1 (es) |
JP (1) | JP2022549810A (es) |
KR (1) | KR20220066894A (es) |
CN (1) | CN114401969A (es) |
AU (1) | AU2020355507A1 (es) |
BR (1) | BR112022003982A2 (es) |
CA (1) | CA3155161A1 (es) |
CO (1) | CO2022003062A2 (es) |
CR (1) | CR20220116A (es) |
IL (1) | IL289617A (es) |
MX (1) | MX2022003023A (es) |
PE (1) | PE20221450A1 (es) |
TW (1) | TW202120502A (es) |
WO (1) | WO2021058416A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
JP7269948B2 (ja) | 2017-11-28 | 2023-05-09 | エフ. ホフマン-ラ ロシュ アーゲー | 新規複素環式化合物 |
EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
CA3104928A1 (en) | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
CA3151516A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
WO2012155199A1 (en) | 2011-05-16 | 2012-11-22 | Bionomics Limited | Amine derivatives as potassium channel blockers |
JP6653319B2 (ja) * | 2015-03-30 | 2020-02-26 | 武田薬品工業株式会社 | 複素環化合物 |
TW201713641A (zh) | 2015-05-13 | 2017-04-16 | 賽爾維他股份公司 | 經取代之喹喏啉衍生物 |
JP7269948B2 (ja) * | 2017-11-28 | 2023-05-09 | エフ. ホフマン-ラ ロシュ アーゲー | 新規複素環式化合物 |
TW201930300A (zh) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
EP3737680A1 (en) * | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
PL3768684T3 (pl) * | 2018-03-22 | 2023-07-10 | F. Hoffmann-La Roche Ag | Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl) |
WO2020035425A1 (en) * | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
CA3104928A1 (en) * | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
-
2020
- 2020-09-21 CA CA3155161A patent/CA3155161A1/en active Pending
- 2020-09-21 US US17/026,619 patent/US20210107921A1/en not_active Abandoned
- 2020-09-21 MX MX2022003023A patent/MX2022003023A/es unknown
- 2020-09-21 EP EP20780603.5A patent/EP4034239A1/en active Pending
- 2020-09-21 KR KR1020227009405A patent/KR20220066894A/ko unknown
- 2020-09-21 BR BR112022003982A patent/BR112022003982A2/pt not_active Application Discontinuation
- 2020-09-21 PE PE2022000376A patent/PE20221450A1/es unknown
- 2020-09-21 JP JP2022518270A patent/JP2022549810A/ja active Pending
- 2020-09-21 CN CN202080063282.3A patent/CN114401969A/zh active Pending
- 2020-09-21 CR CR20220116A patent/CR20220116A/es unknown
- 2020-09-21 WO PCT/EP2020/076228 patent/WO2021058416A1/en unknown
- 2020-09-21 AU AU2020355507A patent/AU2020355507A1/en active Pending
- 2020-09-22 TW TW109132688A patent/TW202120502A/zh unknown
-
2022
- 2022-01-04 IL IL289617A patent/IL289617A/en unknown
- 2022-01-31 US US17/588,816 patent/US20220267349A1/en not_active Abandoned
- 2022-03-17 CO CONC2022/0003062A patent/CO2022003062A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN114401969A (zh) | 2022-04-26 |
CA3155161A1 (en) | 2021-04-01 |
PE20221450A1 (es) | 2022-09-21 |
IL289617A (en) | 2022-03-01 |
US20220267349A1 (en) | 2022-08-25 |
US20210107921A1 (en) | 2021-04-15 |
JP2022549810A (ja) | 2022-11-29 |
KR20220066894A (ko) | 2022-05-24 |
TW202120502A (zh) | 2021-06-01 |
WO2021058416A1 (en) | 2021-04-01 |
EP4034239A1 (en) | 2022-08-03 |
MX2022003023A (es) | 2022-04-07 |
CO2022003062A2 (es) | 2022-04-19 |
BR112022003982A2 (pt) | 2022-05-24 |
AU2020355507A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210247A (es) | Nuevos compuestos heterocíclicos | |
MX2021001433A (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. | |
CR20220116A (es) | Compuestos heterocíclicos | |
MX2020008894A (es) | Inhibidores de oxazin monoacilglicerol lipasa (magl). | |
MX2021000795A (es) | Compuestos heterociclicos para inhibir la actividad de shp2. | |
MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
CR20210056A (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
CR20220118A (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
CR20230496A (es) | Compuestos heterocíclicos | |
MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
EP4248968A3 (en) | Tlr7/8 antagonists and uses thereof | |
AU2020317609A8 (en) | Novel heteroaryl-triazole compounds as pesticides | |
MX2023002224A (es) | Compuestos heterociclicos. | |
MX2022002831A (es) | Compuestos heterociclicos. | |
MX2020002449A (es) | Nuevos compuestos heterociclicos fungicidas. | |
CR20220004A (es) | Nuevos compuestos heterocíclicos | |
MX2022002311A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
MX2022002554A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
MX2021003427A (es) | Nuevos oxadiazoles. | |
WO2018035346A8 (en) | KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER | |
MX2021002188A (es) | Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende. | |
MX2020011671A (es) | Nuevo proceso para la preparacion de diamidas antranilicas. | |
CR20220478A (es) | Derivados de benzodiazepinas como pam de gaba a gamma 1 |